NASDAQ:PLRX Stock Quote
Pliant Therapeutics Inc is a biotechnology company focused on the development of innovative therapies for fibrotic diseases
The company is dedicated to discovering and advancing novel treatments that address the underlying mechanisms of tissue scarring and fibrosis across various organs. By leveraging its expertise in cellular and molecular biology, Pliant aims to transform the lives of patients suffering from debilitating conditions caused by excessive connective tissue growth, ultimately contributing to improved health outcomes and better quality of life.
Frequently Asked Questions
Has Pliant Therapeutics entered any partnerships or collaborations?
Yes, Pliant Therapeutics has established several partnerships and collaborations with other biotech and pharmaceutical companies, as well as academic institutions. These collaborations are aimed at enhancing research and development efforts and accelerating the advancement of its clinical programs.
How can investors stay updated on Pliant Therapeutics?
Investors can stay updated on Pliant Therapeutics by following the company's official website, press releases, and financial statements. Additionally, the company provides updates through earnings calls, investor presentations, and participation in industry conferences.
How does Pliant Therapeutics approach research and development?
Pliant Therapeutics adopts a rigorous and data-driven approach to research and development, emphasizing scientific innovation and patient-centric outcomes. The company engages in preclinical and clinical testing while leveraging real-world evidence to inform therapeutic strategies for fibrotic diseases.
How does Pliant Therapeutics ensure patient safety in clinical trials?
Pliant Therapeutics places a high priority on patient safety during clinical trials by adhering to rigorous ethical standards, regulatory requirements, and best practices in clinical research. The company closely monitors trial participants and collects comprehensive safety data throughout the study.
Is Pliant Therapeutics publicly traded?
Yes, Pliant Therapeutics is publicly traded under the ticker symbol PLRX on the Nasdaq stock exchange. The company went public through an initial public offering (IPO), allowing it to raise capital for further clinical development and operations.
What are the financial prospects for Pliant Therapeutics?
Pliant Therapeutics' financial prospects are influenced by its clinical progress, potential partnerships, and fundraising efforts. Investors generally assess the company's pipeline, market potential, and operational strategies to gauge its future financial performance and sustainability.
What are the future plans for Pliant Therapeutics?
Pliant Therapeutics plans to advance its clinical pipeline, focusing on the development of innovative therapies for fibrotic diseases. The company aims to submit regulatory applications for its lead candidates and expand its research efforts to explore new potential indications and combination therapies.
What are the milestones for Pliant Therapeutics in the next few years?
In the coming years, Pliant Therapeutics anticipates several important milestones, including the completion of ongoing clinical trials, potential regulatory submissions, and updates on additional candidates in its pipeline. These milestones are crucial for advancing their mission of developing effective therapies for fibrotic diseases.
What clinical trials is Pliant Therapeutics currently conducting?
Pliant Therapeutics is currently conducting several clinical trials evaluating PLN-74809 and other drug candidates. These trials are designed to assess the safety, tolerability, and efficacy of their therapies in patients with fibrotic diseases, with results that may inform future treatment options.
What does Pliant Therapeutics, Inc. do?
Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for patients with serious fibrotic diseases. The company leverages its proprietary technology platform, which aims to identify and validate new targets for treatment, ultimately leading to improved patient outcomes.
What impact does the Pliant Therapeutics stock price have on its operations?
The stock price of Pliant Therapeutics can significantly influence its operations by affecting its ability to raise capital, pursue partnerships, and invest in research and development. A stable or growing stock price can enhance financial flexibility and support the company's strategic initiatives.
What is Pliant Therapeutics' lead product candidate?
Pliant Therapeutics' lead product candidate is PLN-74809, which is currently in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. The drug is designed to inhibit a specific signaling pathway that contributes to the progression of fibrosis.
What is the competitive landscape for Pliant Therapeutics?
The competitive landscape for Pliant Therapeutics includes other biotechnology and pharmaceutical companies focused on fibrotic diseases, particularly those developing novel therapies for conditions such as idiopathic pulmonary fibrosis. Pliant aims to differentiate itself through its unique approach and robust pipeline.
What is the mission of Pliant Therapeutics?
The mission of Pliant Therapeutics is to improve the lives of patients suffering from serious fibrotic diseases through innovative therapies. The company is committed to conducting rigorous scientific research and clinical development to bring effective treatments to market.
What is the significance of the proprietary technology platform of Pliant Therapeutics?
Pliant Therapeutics has developed a proprietary technology platform that integrates advanced screening, validation, and optimization methodologies. This platform is essential in identifying new drug targets and enables the company to rapidly advance its candidates through the drug development pipeline.
What types of therapies does Pliant Therapeutics focus on?
Pliant Therapeutics focuses on developing therapies that target fibrotic diseases, which are characterized by the excessive accumulation of connective tissue and scar formation. This includes conditions such as idiopathic pulmonary fibrosis, systemic sclerosis, and other indications where fibrosis plays a critical role in disease progression.
When was Pliant Therapeutics founded?
Pliant Therapeutics was founded in 2015. Since its inception, the company has focused on advancing its pipeline of drug candidates aimed at treating fibrotic diseases and has rapidly grown its capabilities through both internal development and strategic partnerships.
Where is Pliant Therapeutics headquartered?
Pliant Therapeutics is headquartered in South San Francisco, California. This strategic location in the heart of one of the world's leading biopharmaceutical hubs allows the company to collaborate with top-tier research institutions and attract talent in the life sciences sector.
Who are the key executives at Pliant Therapeutics?
Pliant Therapeutics is led by a seasoned management team with extensive experience in the biopharmaceutical industry. Key executives include the CEO, President, and Chief Scientific Officer, who collectively bring a wealth of knowledge in drug development, commercialization, and corporate strategy.
What is the current price of Pliant Therapeutics, Inc. - Common Stock?
The current price of Pliant Therapeutics, Inc. - Common Stock is 1.415
When was Pliant Therapeutics, Inc. - Common Stock last traded?
The last trade of Pliant Therapeutics, Inc. - Common Stock was at 2:24 pm EDT on April 2nd, 2025
What is the market capitalization of Pliant Therapeutics, Inc. - Common Stock?
The market capitalization of Pliant Therapeutics, Inc. - Common Stock is 50.85M
How many shares of Pliant Therapeutics, Inc. - Common Stock are outstanding?
Pliant Therapeutics, Inc. - Common Stock has 35.94M shares outstanding.